Taconic Biosciences releases COVID-19 mouse model

By The Science Advisory Board staff writers

April 29, 2021 -- Taconic Biosciences announced it has developed a human angiotensin-converting enzyme 2 (hACE2) AC22 lethality-resistant transgenic mouse model that will permit the study of sublethal COVID-19 infection.

Taconic launched its first hACE2 model in October 2020. The mouse experiences a lethal response to infection by SARS-CoV-2. Conversely, the new AC22 mouse is lethality-resistant when infected, which will enable therapeutic, vaccine, and postinfection symptom research, the company stated.

Study-ready cohorts of animals are available for immediate ordering, Taconic reported.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.